
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
Which drugs were most popular in 2009? Check out Drug Topics' list of the Top 200 generic drugs in 2009, ranked by total prescriptions.






